By Joe Hoppe

C4X Discovery Holdings PLC said Monday that it has signed a worldwide licensing deal with AstraZeneca PLC worth up to $402 million for the development and commercialization of its NRF2 Activator program.

The drug discovery company said it was eligible to receive pre-clinical milestone payments worth up to $16 million ahead of the first clinical trial, including $2 million upfront. The deal also includes payments for development and commercial milestones, and tiered mid-single digit royalties.

The company said AstraZeneca will develop and commercialize an oral therapy for the treatment of inflammatory and respiratory diseases, with a lead focus on chronic obstructive pulmonary disease.

Write to Joe Hoppe at joseph.hoppe@wsj.com

(END) Dow Jones Newswires

November 28, 2022 02:49 ET (07:49 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Gráfico Histórico do Ativo
De Jan 2023 até Fev 2023 Click aqui para mais gráficos Astrazeneca.
Astrazeneca (LSE:AZN)
Gráfico Histórico do Ativo
De Fev 2022 até Fev 2023 Click aqui para mais gráficos Astrazeneca.